# DESCRIPTION

## BACKGROUND

- introduce tauopathies
- describe tau protein structure and function

## SUMMARY

- disclose monoclonal antibodies
- describe methods and kits for detecting and treating tauopathies

## DETAILED DESCRIPTION

- define singular and plural forms
- define preventing and treating
- define effective amount and therapeutically effective amount
- define subject
- define antibody
- describe antibody structure and properties
- define variable region and variable domain
- describe complementarity determining regions and framework regions
- define full-length antibody and antibody fragment
- describe Fab, F(ab′)2, and Fv fragments
- define single-chain Fv and chimeric antibody
- define humanized antibody and human antibody
- define intrabody and complementarity determining region
- define percent amino acid sequence identity
- define homology
- introduce sequence alignment programs
- define vector
- define plasmid
- define host cell
- introduce SEQ ID NOs
- describe tauopathies
- describe microtubule binding domain of tau
- introduce disclosed antibodies
- describe specificity of disclosed antibodies
- describe use of disclosed antibodies
- introduce monoclonal antibodies
- describe epitopes recognized by disclosed antibodies
- describe light chain and heavy chain CDRs
- describe antibody or antigen binding fragments
- describe antibody preparation
- describe polyclonal and monoclonal antibody production
- introduce monoclonal antibodies
- describe DNA isolation and sequencing
- express antibodies in host cells
- generate antibodies using phage libraries
- modify DNA encoding antibodies
- create chimeric antibodies
- describe humanized antibodies
- choose human variable domains
- design humanized antibodies
- prepare human tau antibodies
- use transgenic animals
- employ phage display technology
- use ribosome display technology
- prepare human tau monoclonal antibodies
- describe intrabodies
- express intrabodies in target cells
- produce antibody fragments
- engineer effector function
- modify Fc receptor binding site
- incorporate salvage receptor binding epitope
- describe tau antibodies and antigen binding fragments
- describe methods of treating or preventing tauopathies
- describe pharmaceutical compositions
- describe diagnostic methods
- describe production of tau antibodies and antigen binding fragments
- describe materials and methods
- describe production and purification of recombinant tau and α-synuclein proteins
- describe generation of new mouse monoclonal antibodies
- describe hybridoma screening
- describe preparation of total mouse brain protein lysates
- describe preparation of sarkosyl-insoluble human temporal cortex
- describe immunoblotting
- describe immunohistochemistry
- describe incorporation of references
- describe scope of the invention

## EXAMPLES

### Example 1: Generation of Antibodies Targeting the Microtubule Binding Domain of Tau

- generate antibodies targeting MTBD of tau
- characterize antibodies using ELISA, immunoblots, and immunohistochemistry

### Example 2: Characterization of Antibodies with Human Post-Mortem Ad and Psp Tissue

- characterize antibodies using immunoblotting and immunohistochemistry with human AD and PSP tissue

### Example 3

- summarize monoclonal tau antibodies
- describe reactivity of antibodies with mouse brain tissue
- describe reactivity of antibodies with human AD and PSP tissue
- discuss therapeutic potential of antibodies for tauopathies

